Tianjin Medical University Cancer Institute and Hospital-ko ikertzaileekin lankidetzan egindako argitalpenak (1)

2023

  1. ROSEWOOD: A Phase II Randomized Study of Zanubrutinib Plus Obinutuzumab Versus Obinutuzumab Monotherapy in Patients with Relapsed or Refractory Follicular Lymphoma

    Journal of Clinical Oncology